期刊文献+

PALB2基因rs249954位点单核苷酸多态性与乳腺癌发病风险关系的meta分析 被引量:1

Association between a single nucleotide polymorphism in PALB2 rs249954 and breast cancer: a meta-analysis
原文传递
导出
摘要 目的探究乳腺癌易感基因PALB2 rs249954位点单核苷酸多态性与乳腺癌发病风险的关系。方法检索中国知网(CNKI)、万方、中国生物医学文献数据库(CBM)、Pub Med、Embase、Cochrane Library、Science Direct及Web of Science数据库,搜索国内外有关乳腺癌PALB2 rs249954位点单核苷酸多态性的文献,依据纳入标准、排除标准以及质量评价原则,筛选出符合要求的文献,使用Stata 14.0软件进行meta分析并对发表偏移进行评估。结果共纳入7篇符合要求的研究,累积乳腺癌病例3 247例,累积对照3 294例。meta分析结果显示,等位基因模型[T vs C:OR=1.14,95%CI为(0.95,1.37),P=0.156]、显性基因模型[CT+TT vs CC:OR=1.22,95%CI为(0.97,1.54),P=0.088]、隐性基因模型[TT vs CT+CC:OR=1.11,95%CI为(0.84,1.45),P=0.464]、共显性基因模型CC vs TT[OR=0.79,95%CI为(0.54,1.15),P=0.226]及共显性基因模型TT vs CT[OR=0.95,95%CI为(0.82,1.11),P=0.523]的合并OR值均无统计学意义;共显性基因模型CC vs CT[OR=0.82,95%CI为(0.67,1.00),P=0.048]的合并OR值具有统计学意义,但敏感性分析示结果不具有稳定性;超显性基因模型的合并OR值具有统计学意义[CC+TT vs CT:OR=0.85,95%CI为(0.77,0.94),P=0.001],相比于CC+TT,CT杂合子基因型可增加乳腺癌的发病风险。结论 PALB2 rs249954位点的突变型CT杂合子基因型相对于CC+TT基因型可增加乳腺癌的发病风险。 Objective To explore the association between a single nucleotide polymorphism in PALB2 rs249954 and breast cancer. Methods Studies regarding the association between a single nucleotide polymorphism in PALB2 rs249954 and breast cancer were searched from CNKI, WanFang, CBM, PubMed, Embase, Cochrane Library, Science Direct, and Web of Science. The eligible studies were screened based on the inclusion, exclusion criteria, and principle of quality evaluating. Meta-analysis and the assessment of published bias were performed by Stata 14.0 software. Results A total of 7 studies were eligible for this study, including 3 247 cumulative cases of breast cancer and 3 294 controls. Through the comparison of a variety of genetic models, we found that there was no significant for the OR of additive model (T vs C: OR=1.14, 95% C/was (0.95, 1.37), P=0.1561, dominant gene model (CT+TT vs CC: OR=1.22, 95% C/was (0.97, 1.54), P=0.088), recessive gene model (TT vs CT+CC: OR=I.ll, 95% CI was (0.84, 1.45), P=0.464), codominant gene model CC vs TT and TT vs CT ( OR=0.79, 95% C/was (0.54, 1.15), P=0.226; OR=0.95, 95% C/was (0.82, 1.11), P=0.523 }; there was significant difference for codominant gene model CC vs CT ( OR=0.82, 95% CI was (0.67, 1.00), P=0.048), but the conclusion was different after sensitivity analysis. Besides, there was notable difference for overdominant model ( CC+TT vs CT: OR=0.85, 95% CI was (0.77, 0.94), P=0.001 ). Conclusion The mutant genotype heterozygous (CT) of rs249954 in PALB2 will increase the breast cancer risk.
出处 《中国普外基础与临床杂志》 CAS 2017年第9期1112-1121,共10页 Chinese Journal of Bases and Clinics In General Surgery
关键词 乳腺癌 PALB2基因 rs249954位点 多态性 META分析 breast cancer PALB2 gene rs249954 loci polymorphism meta-analysis
  • 相关文献

参考文献3

二级参考文献35

  • 1Song CG,Hu Z,Wu J,et al.The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer[J].J Cancer Res Clin Oncol,2006,132(10):617-626.
  • 2Hu Z,Song CG,Lu JS,et al.A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha,COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives[J].J Cancer Res Clin Oncol,2007,133(12):969-978.
  • 3Xia B,Sheng Q,Nakanishi K,et al.Control of BRCA2 cellular and clinical functions by a nuclear partner,PALB2[J].Mol Cell,2006,22(6):719-729.
  • 4Rahman N,Seal S,Thompson D,et al.PALB2,which encodes a BRCA2-interacting protein,is a breast cancer susceptibility gene[J].Nat Genet,2007,39(2):165-167.
  • 5Chen P,Liang J,Wang Z,et al.Association of common PALB2 polymorphisms with breast cancer risk:a case control study[J].Clin Cancer Res,2008,14(18):5931-5937.
  • 6Cao AY,Huang J,Hu Z,et al.The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives[J].Breast Cancer Res Treat,2009,114(3):457-462.
  • 7Milne AN,Carneiro F,O'Morain C,et al,Nature meets nurture:molecular genetics of gastric cancer[J].Hum Genet,2009,126(5):615-628.
  • 8Lee DH,Hahm KB.Inflammatory cytokine gene polymorphisms and gastric cancer[J].J Gastroenterol Hepatol,2008,23(10):1470-1472.
  • 9Moher D,Liberati A,Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J].Annals of Internal Medicine,2009.264-269.
  • 10Moher D,Cook D J,Eastwood S. Improving the quality of reports of meta-analyses of randomised controlled trials:the QUOROM statement[J].The Lancet,1999.1896-1900.

共引文献325

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部